Association of In-Hospital Hemoglobin Drop With Decreased Myocardial Salvage and Increased Long-Term Mortality in Patients With Acute ST-Segment-Elevation Myocardial Infarction.
blood loss
hemoglobin
infarct size
myocardial infarction
single‐photon emission computed tomography imaging
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
06 09 2022
06 09 2022
Historique:
pubmed:
25
8
2022
medline:
9
9
2022
entrez:
24
8
2022
Statut:
ppublish
Résumé
Background Anemia and blood loss occur often in patients with ST-segment-elevation myocardial infarction (STEMI). In-hospital hemoglobin drop is associated with 1-year mortality in patients with acute coronary syndrome. However, data on the effect of hemoglobin reduction on myocardial salvage and long-term outcomes are scarce. We investigated the impact of in-hospital hemoglobin drop on myocardial salvage and 5-year mortality in patients with STEMI treated with primary percutaneous coronary intervention. Methods and Results In-hospital hemoglobin drop was defined as a decrease in hemoglobin levels from admission and nadir hemoglobin values. Patients were categorized as having the following: no drop, minimal drop (<3 g/dL), minor drop (≥3 to <5 g/dL), and major drop (≥5 g/dL). Myocardial area at risk and infarct size were measured using serial single-photon emission computerized tomography imaging. The co-primary outcomes were myocardial salvage and 5-year all-cause mortality. Of 1204 patients, 1169 (97.1%) showed a hemoglobin drop during hospitalization: minimal, minor, and major drop occurred in 894 (74.3%), 214 (17.8%), and 61 (5.1%) patients, respectively. Myocardial salvage was reduced in patients with minimal (median, 0.53 [interquartile range, 0.27-0.83]), minor (median, 0.40 [interquartile range, 0.18-0.62]), and major (median, 0.40 [interquartile range, 0.14-0.77]) drop compared with patients without drop (median, 0.70 [interquartile range, 0.44-1.0],
Identifiants
pubmed: 36000430
doi: 10.1161/JAHA.121.024857
pmc: PMC9496425
doi:
Substances chimiques
Hemoglobins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e024857Subventions
Organisme : British Heart Foundation
Pays : United Kingdom
Références
Eur Heart J. 2007 Jun;28(11):1289-96
pubmed: 17363447
Q J Nucl Med Mol Imaging. 2016 Sep;60(3):185-93
pubmed: 27273431
J Am Heart Assoc. 2016 Nov 19;5(11):
pubmed: 27866165
J Thorac Dis. 2017 Mar;9(Suppl 1):S30-S35
pubmed: 28446966
Eur Heart J. 2021 Apr 7;42(14):1289-1367
pubmed: 32860058
Nature. 2021 Apr;592(7855):524-533
pubmed: 33883728
JAMA. 2021 Feb 9;325(6):552-560
pubmed: 33560322
Am J Cardiol. 2017 Jun 15;119(12):1909-1916
pubmed: 28450037
Circulation. 2018 Feb 27;137(9):961-972
pubmed: 29483172
J Am Heart Assoc. 2019 Nov 19;8(22):e013703
pubmed: 31701786
Eur J Clin Invest. 2021 Dec;51(12):e13670
pubmed: 34541662
J Transl Med. 2019 May 29;17(1):180
pubmed: 31142323
Nephrol Dial Transplant. 2000;15 Suppl 3:14-8
pubmed: 11032352
EuroIntervention. 2011 May;7(1):128-35
pubmed: 21550913
J Cardiovasc Transl Res. 2020 Aug;13(4):618-628
pubmed: 31768948
J Am Coll Cardiol. 2021 Feb 2;77(4):375-388
pubmed: 33509394
Circulation. 2005 Apr 26;111(16):2042-9
pubmed: 15824203
J Am Coll Cardiol. 2010 May 25;55(21):2383-9
pubmed: 20488311
Circ Cardiovasc Qual Outcomes. 2010 Jul;3(4):337-46
pubmed: 20488919
Eur Heart J. 2007 Jun;28(11):1273-4
pubmed: 17483543
Ann Intern Med. 2013 Dec 3;159(11):746-757
pubmed: 24297191